Blog

This year began with significant uncertainty for the healthcare market due to proposed tariffs, potential CMS policy and reimbursement changes, and overall financial market challenges. In the second half of 2025, we are seeing more decisive action in MedTech, both from venture capital investment and acquisitions of growth stage companies. But a trend is starting to develop in the other direction as well. Some MedTech giants are looking to streamline their diverse portfolios, spinning some divisions off into new companies.

Simon Labute, Staff Software Engineer, Applications, explains why he loves working at AcuityMD, the ownership and room to grow he has on his projects, and how our culture is different than any other place he's been before.

A new report shows that more physicians are leaving independently-owned groups and either returning to a hospital setting or private-equity backed practices. This trend, combined with the fact that nearly 10,000 physicians are retiring every year, means that even veteran reps who know their territories inside and out have to work harder than ever to stay on top of the latest trends.

The rules of MedTech sales have changed. Innovative new treatments still capture attention, but the increased scrutiny that comes with value analysis committees and value based care programs mean that MedTech companies need to prove the impact of new technologies with hard data.

Bringing a new medical device to market is one of the most expensive and time-intensive endeavors in all of business. For startup and growth-stage companies with limited runway remaining, this is where dreams either become terrific realities or expensive failures.

For many companies, particularly those growing quickly, commercial excellence can be the difference between accelerating growth or stalling out. The complexity of MedTech sales cycle - with its long timelines, purchasing decisions influenced by diverse stakeholders, and compliance issues - make it even more important.

At AcuityMD we've been bullish on AI since the launch of our very first entity resolution algorithm. But we've been blown away by how quickly agentic AI, AI that takes action proactively, is reshaping how we can build new products.

The medical device industry stands at an inflection point. While AI has already transformed product development and clinical applications, its potential for commercial transformation remains largely untapped. Companies that recognize this opportunity and act decisively will gain sustainable competitive advantages in a challenging market.

Artificial intelligence in healthcare is no longer just a future possibility. It's already fundamentally changing how medical professionals deliver care and how patients experience treatment.

MedTech funding surged to $3.7B in Q1 2025 with larger deals but fewer investments. Learn how to position your company for today's selective market.

Developing a new data solution always takes teamwork. Sometimes it’s a straightforward project with a tried and true playbook. But sometimes you realize that you have to make something that doesn’t exist at all. Then the challenge for data analysts, designers, and developers is not just figuring out how to fill a blank canvas, but how to create the canvas itself.

Healthcare experts anticipated policy shifts in 2025, but many have been surprised by how quickly extensive changes have come. Health systems, MedTech companies, and payers are all being challenged to gauge the financial and clinical impacts of recent announcements.

MedTech sales reps that want to create educational events or marketing campaigns that connect PCPs to the HCPs offering their newest treatment have no way to know who to target without a lot of legwork or guesswork. As a result, patients are often referred for either less effective treatments, simply because their PCP isn’t aware that better options exist.

MedTech sales reps are burdened with too many manual tasks that take valuable time away from actually selling. AI can help reps by automating these tasks.

Insights into how payers are reimbursing certain procedures and providers enables MedTech companies to focus on the opportunities with the highest potential for product adoption and revenue growth.

Securing contracts with IDNs and GPOs is becoming more important for MedTech companies in order to maximize sales. Unfortunately, most companies don’t have a plan or process that allows them to tap into the potential revenue of these contracts.

CRM platforms have long been the go-to tool for sales and marketing teams to track their sales cycles and activities. However, they often fail to deliver real value, especially in MedTech.

The transition to commercialization is an exciting milestone, but it’s critical to get it right. Marketing, sales, sales operations, R&D, finance, supply chain, leadership, and advisory boards are all stakeholders and they all need to be singing from the same sheet of music to get a product launch right.

Our mission at AcuityMD is accelerating the adoption of medical technology because we know that ultimately leads to better patient care. That’s why we’re so excited to share our newest solution, AcuityMD Care Journeys. This first-of-its-kind experience shows a full view of longitudinal patient data to provide a clear understanding of the journey for patients with complex clinical histories.

Flywheel is quickly becoming the event for MedTech commercial leaders to stay ahead of market trends and take the latest best practices back to their organizations, and we know it’s going to get bigger and better every year.